In:
Liver International, Wiley, Vol. 34, No. 10 ( 2014-11), p. 1550-1559
Abstract:
Pretreatment identification of patients likely to achieve a sustained virological response ( SVR ) with peginterferon alfa‐2a/ribavirin would be useful for individualizing treatment choices. The aim of this analysis was to devise a simple scoring system to identify patients with high probability of achieving an SVR with peginterferon alfa‐2a/ribavirin. Methods Using data from 2109 Caucasian treatment‐naive hepatitis C virus ( HCV ) genotype 1 mono‐infected patients from the PROPHESYS cohorts, the relationship between favourable baseline characteristics and SVR was explored using generalized additive model analysis, and a scoring system was devised to predict SVR . Results Points were assigned for: age (years) (≤35: 2; 〉 35, ≤45: 1; 〉 45: 0); body mass index (kg/m 2 ) (≤20: 2; 〉 20, ≤22: 1; 〉 22: 0); HCV RNA (IU/ml) (≤100 000: 3; 〉 100 000–400 000: 2; 〉 400 000–800 000: 1; 〉 800 000: 0); platelets ( 〉 150 ×10 9 /l: 1; ≤150 ×10 9 /l: 0); alanine aminotransferase [×upper limit of normal ( ULN )] ( 〉 3: 1; ≤3: 0); serum aspartate aminotransferase (× ULN ) (≤1: 1; 〉 1: 0). 1029, 698 and 382 patients had scores of 0–2, 3–4 and ≥5, respectively, among whom SVR rates were 35.0, 54.9 and 76.7%. SVR in patients with scores ≥5 and undetectable HCV RNA by week 4 was 86.7%. The score was tested against two databases of patients who received peginterferon alfa‐2a/ribavirin in other clinical trials; similar high SVR rates in patients with scores ≥5 were reported. Conclusions The scoring system can reliably identify treatment‐naive HCV genotype 1 mono‐infected Caucasian patients who have a high probability of achieving an SVR with peginterferon alfa‐2a/ribavirin and will be particularly useful where protease inhibitors are not readily available.
Type of Medium:
Online Resource
ISSN:
1478-3223
,
1478-3231
DOI:
10.1111/liv.2014.34.issue-10
Language:
English
Publisher:
Wiley
Publication Date:
2014
detail.hit.zdb_id:
2124684-1
